Barrington Of Carmel, The | |
1335 S Guilford Road, Carmel, Indiana 46032 | |
(317) 810-1800 | |
Name | Barrington Of Carmel, The |
---|---|
Location | 1335 S Guilford Road, Carmel, Indiana |
Certified By | Medicare |
No. of Certified Beds | 48 |
Occupancy Rate | 58.13% |
Medicare ID (CCN) | 155817 |
Legal Business Name | Prairie Landing Community Inc |
Ownership Type | Non Profit - Corporation |
NPI Number | 1265089601 |
Organization Name | PRAIRIE LANDING COMMUNITY INC |
Address | 1335 S Guilford Rd, Carmel, IN 46032 |
Phone Number | 317-810-1800 |
News Archive
Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
A gene has been identified by researchers at King's College London that is thought to be associated with the types of brain damage that can be caused by pre-term birth.
Health authorities should develop targeted health messages for vaping product and e-liquid packaging to encourage smokers to switch from cigarettes to e-cigarettes and to prevent non-smokers from taking up vaping, a researcher at the University of Otago, Wellington, New Zealand says.
Assembling a drug from harmless components at the target location, such as a tumor, would help reduce the side effects of treatment.
› Verified 4 days ago
NPI Number | 1689016594 |
Organization Name | MAYFLOWER COMMUNITIES INC. |
Doing Business As | THE BARRINGTON OF CARMEL |
Address | 1335 S Guilford Rd, Carmel, IN 46032 |
Phone Number | 317-706-6760 |
News Archive
Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
A gene has been identified by researchers at King's College London that is thought to be associated with the types of brain damage that can be caused by pre-term birth.
Health authorities should develop targeted health messages for vaping product and e-liquid packaging to encourage smokers to switch from cigarettes to e-cigarettes and to prevent non-smokers from taking up vaping, a researcher at the University of Otago, Wellington, New Zealand says.
Assembling a drug from harmless components at the target location, such as a tumor, would help reduce the side effects of treatment.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
A gene has been identified by researchers at King's College London that is thought to be associated with the types of brain damage that can be caused by pre-term birth.
Health authorities should develop targeted health messages for vaping product and e-liquid packaging to encourage smokers to switch from cigarettes to e-cigarettes and to prevent non-smokers from taking up vaping, a researcher at the University of Otago, Wellington, New Zealand says.
Assembling a drug from harmless components at the target location, such as a tumor, would help reduce the side effects of treatment.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 9.52 | 14.46 |
Percentage of long-stay residents who lose too much weight | 14.93 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.27 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 7.06 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.2 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.35 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 16.47 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.86 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0.92 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 10.55 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.42 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 10.94 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.07 | 95.98 |
Percentage of short-stay residents who made improvements in function | 81.74 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80.93 | 82.93 |
News Archive
Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
A gene has been identified by researchers at King's College London that is thought to be associated with the types of brain damage that can be caused by pre-term birth.
Health authorities should develop targeted health messages for vaping product and e-liquid packaging to encourage smokers to switch from cigarettes to e-cigarettes and to prevent non-smokers from taking up vaping, a researcher at the University of Otago, Wellington, New Zealand says.
Assembling a drug from harmless components at the target location, such as a tumor, would help reduce the side effects of treatment.
› Verified 4 days ago
Carmel Health & Living Community Location: 118 Medical Dr, Carmel, Indiana 46032 Phone: (317) 844-4211 | |
Manor Care Health Services Summer Trace Location: 12999 N Pennsylvania St, Carmel, Indiana 46032 Phone: (317) 848-2448 | |